Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)

被引：0
|
作者：
Benjamin Daniels
Belinda E Kiely
Nehmat Houssami
Sarah J Lord
Timothy Dobbins
Christine Y Lu
Robyn L Ward
Sallie-Anne Pearson
机构：
[1] Medicines Policy Research Unit,Department of Population Medicine
[2] Centre for Big Data Research in Health,undefined
[3] University of New South Wales,undefined
[4] NHMRC Clinical Trials Centre,undefined
[5] University of Sydney,undefined
[6] Sydney School of Public Health,undefined
[7] Sydney Medical School,undefined
[8] University of Sydney,undefined
[9] School of Medicine,undefined
[10] University of Notre Dame Australia,undefined
[11] National Drug and Alcohol Research Centre,undefined
[12] University of New South Wales,undefined
[13] Harvard Medical School and Harvard Pilgrim Health Care Institute,undefined
[14] University of Queensland,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
trastuzumab; breast cancer; metastatic; adjuvant; neoadjuvant; overall survival; population-based; routinely collected data;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：441 / 447
页数：6
相关论文
共 50 条
  • [1] Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006-2014)
    Daniels, Benjamin
    Kiely, Belinda E.
    Houssami, Nehmat
    Lord, Sarah J.
    Dobbins, Timothy
    Lu, Christine Y.
    Ward, Robyn L.
    Pearson, Sallie-Anne
    BRITISH JOURNAL OF CANCER, 2018, 118 (03) : 441 - 447
  • [2] Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study
    Monica Tang
    Andrea L. Schaffer
    Belinda E. Kiely
    Benjamin Daniels
    Chee K. Lee
    Robert J. Simes
    Sallie-Anne Pearson
    Breast Cancer Research and Treatment, 2021, 187 : 893 - 902
  • [3] Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study
    Tang, Monica
    Schaffer, Andrea L.
    Kiely, Belinda E.
    Daniels, Benjamin
    Lee, Chee K.
    Simes, Robert J.
    Pearson, Sallie-Anne
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 893 - 902
  • [4] Survival outcomes for polish women younger than age 40 years receiving trastuzumab for HER2-positive early breast cancer: A National population-based observational study.
    Jagielska, Beata
    Jagiello-Gruszfeld, Agnieszka Irena
    Talasiewicz, Konrad
    Czubek, Andrzej
    Krzakowski, Maciej Jerzy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Observational study on adjuvant trastuzumab in HER2-positive early breast cancer patients
    Mustacchi, G.
    Puglisi, F.
    Molino, A. M.
    Crivellari, D.
    Ghiotto, C.
    Ferro, A.
    Brunello, A.
    Saracchini, S.
    Turazza, M.
    Cretella, E.
    Iop, A.
    Malagoli, M.
    Stefani, M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1493 - 1500
  • [6] Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort
    Daniels, Benjamin
    Kiely, Belinda E.
    Tang, Monica
    Houssami, Nehmat
    Lord, Sarah J.
    Pearson, Sallie-Anne
    BREAST, 2021, 58 : 106 - 112
  • [7] Effect of Adjuvant/Neoadjuvant Trastuzumab on Clinical Outcomes in Patients With HER2-Positive Metastatic Breast Cancer
    Murthy, Rashmi K.
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana
    Murray, James L.
    Koenig, Kimberly H.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Giordano, Sharon H.
    Booser, Daniel
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    CANCER, 2014, 120 (13) : 1932 - 1938
  • [8] Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly
    van Rooijen, Johan M.
    de Munck, Linda
    Teeuwen, Guusje M.
    de Graaf, Jacques C.
    Jansman, Frank G.
    Boers, James E.
    Siesling, Sabine
    ANTI-CANCER DRUGS, 2016, 27 (02) : 127 - 132
  • [9] Trastuzumab improves survival, outcomes of HER2-positive breast cancer patients
    不详
    FORMULARY, 2006, 41 (03) : 146 - +
  • [10] Paclitaxel, Carboplatin, and Trastuzumab in a Neo-adjuvant Regimen for HER2-positive Breast Cancer
    Sonke, Gabe S.
    Mandjes, Ingrid A.
    Holtkamp, Marjo J.
    Schot, Margaret
    van Werkhoven, Erik
    Wesseling, Jelle
    Peeters, Marie-Jeanne Vrancken
    Rodenhuis, Sjoerd
    Linn, Sabine C.
    BREAST JOURNAL, 2013, 19 (04): : 419 - 426
12345